Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.63 |
| ▸ | GSK3B | P49841 | 1/20 | 0.63 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.63 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.63 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 8/20 | 0.56 |
| ▸ | MAPT | P10636 | 12/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4285556 | 1.00 | CLK1 (0.63) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| SCHEMBL4062572 | 0.90 | CLK1 (0.58) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| SCHEMBL4062708 | 0.81 | CLK1 (0.93) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| SCHEMBL4066326 | 0.81 | MAPT (0.77) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| SCHEMBL4063265 | 0.78 | CLK1 (1.00) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| SCHEMBL30697294 | 0.78 | CLK1 (1.00) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| SCHEMBL4795234 | 0.78 | CLK1 (0.85) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| SCHEMBL4060137 | 0.78 | MAPT (0.82) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| Acetic Acid SCHEMBL4066978 | 0.74 | CLK1 (0.91) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| SCHEMBL4066988 | 0.73 | HTT (1.00) | CLK1GSK3BDYRK1ACLK4DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883504-B2 | Cell differentiation suppressing agent, method of culturing cells using the same, culture solution, and cultured cell line | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2014-11-11 | — | — | US | disclosed |
| EP-1960777-B1 | SERUM-FREE EXPANSION OF CELLS IN CULTURE | CHOONGWAE PHARMA CORP (KR) | 2009-10-21 | — | — | EP | disclosed |
| US-20090155906-A1 | CELL DIFFERENTIATION SUPPRESSING AGENT, METHOD OF CULTURING CELLS USING THE SAME, CULTURE SOLUTION, AND CULTURED CELL LINE | MIYABAYASHI TOMOYUKI | 2009-06-18 | — | — | US | disclosed |
| US-20070128669-A1 | Serum-free expansion of cells in culture | INSTITUTE FOR CHEMICAL GENOMICS (US) | 2007-06-07 | — | — | US | disclosed |
| EP-1640449-A1 | CELL DIFFERENTIATION INHIBITING AGENT, CELL CULTURE METHOD USING THE SAME, CULTURE MEDIUM AND CULTURED CELL LINE | Asahi Kasei Kabushiki Kaisha (JP) | 2006-03-29 | — | — | EP | disclosed |
| US-20050153941-A1 | Increasing Stage Specific Embryonic Antigen (SSEA) and Nanog gene levels; culturing a stem cell using a low molecular weight derivative of 2-(phenylazo)-2-(3,4-dihydro-2H-isoquinoline-1-ylidene) or N-phenylindole | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153941-A1 | Increasing Stage Specific Embryonic Antigen (SSEA) and Nanog gene levels; culturing a stem cell using a low molecular weight derivative of 2-(phenylazo)-2-(3,4-dihydro-2H-isoquinoline-1-ylidene) or N-phenylindole | MKI67, ALPG, NES | CLK1 4264/4885GSK3B 3504/4885DYRK1A 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.